AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03387748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gesture elicitation
Description: * Participants are required to gesture with their hands (and not speaking) one by one 30 pictures from the Boston Naming Task which appear on a laptop screen.~* Participants retell a cartoon to the researcher~* The researcher initiates a 10-min spontaneous conversation.~These three tasks are video-recorded.
Study NCT03760731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for Moral Injury (ACT-MI)
Description: Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
Study NCT03760731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy (PCT)
Description: Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right.
Study NCT02593721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Median Nerve Neural Mobilization
Description: Non-surgical non-invasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
Study NCT02593721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: The active comparator group received an oral Ibuprofen treatment. The starting dose was of 400 mg/day and it was increased to a maximum of 1200 mg/day divided in 3 oral intakes every 8 hours depending on patient tolerance.The intervention was applied during a period of 6 weeks.
Study NCT00229437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-128
Description: TAK-128 5 mg, tablets, orally, once daily for up to 6 months.
Study NCT00229437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-128
Description: TAK-128 50 mg, tablets, orally, once daily for up to 6 months.
Study NCT00229437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-128
Description: TAK-128 100 mg, tablets, orally, once daily for up to 6 months.
Study NCT00229437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.
Study NCT02796300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioflo Dialysis Catheter
Description: The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
Study NCT02796300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palindrome Dialysis Catheter
Description: The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
Study NCT02241005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theraworx™ bath wipes
Description: Theraworx™ bath wipes will be supplied in packaging similar to the standard bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
Study NCT02241005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard bath wipes
Description: Standard bath wipes will be supplied in packaging similar to the Theraworx™ bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
Study NCT04245774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (as Levobupivacaine Hydrochloride) 75 Mg/10 mL Solution for Injection Ampoule
Description: 7,5 mg (1.5 mL) of 0,5% hyperbaric levobupivacaine (1 mL 0.75% isobaric levobupivacaine (Chirocaine® 75 mg/10mL ampoule Abbott/Turkey, Nycomed Pharma/Norway) plus 0.24 mL 50% Dextrose (dextrose 120 mg) (Eczacıbaşı/Turkey) and 0.26 mL distilled water) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
Study NCT02698605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usability test study of the MirrorPath
Description: The study was conducted by research assistants. Each subject received one assessment that last lasted 30 minutes. The subjects were not paid for participation. In that, no randomization or masking were performed. Prior to the experiment part of the study, the subjects provided basic biographical information. We then explained the experimental process and demonstrated the operation of the device.~A novel rehabilitation device, the MirrorPath, designed for the upper limb rehabilitation of patients with hemiplegic stroke. The MirrorPath that was 1180x440x300mm in size and had a shell was constructed of acrylonitrile butadiene styrene (ABS). The control module featured an on/off switch, a knob for adjusting the speed, and an emergency cutoff switch.
Study NCT04674696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Approach
Description: Patients will receive 2 CAPOX cycles, followed by short-course radiotherapy and 4 CAPOX cycles.
Study NCT03882541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: To evaluate the effect of music in patients anxiety and pain during perioperative process in surgical intervention with regional anaesthesia without sedatives or anxiolytics.
Study NCT03882541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation with midazolam
Description: To evaluate the effect of sedation (in comparation with music group) in patients anxiety and pain durin perioperative process in surgical intervention with regional anesthesia without music
Study NCT04293692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 0.5\*10E6 UC-MSCs /kg body weight suspended in 100mL saline containing 1% human albumin intravenously at Day1, Day3, Day5, Day7
Study NCT04293692 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL saline containing 1% human albumin intravenously at Day 1, Day 3, Day 5, Day 7
Study NCT01587027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: Aminophylline dosage form-tablet dosage-500mg
Study NCT01587027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methazolamide
Description: Methazolamide dosage form-tablet dosage-250mg
Study NCT01587027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline and Methazolamide
Description: Aminophylline 500mg orally and Methazolamide 250mg orally
Study NCT01417143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258 (Dovitinib):
Description: TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
Study NCT04294953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Each Patient will receive oral Duloxetine capsule 60mg at the night before operation(12hrs before surgery), the 2nd dose 60 mg Duloxetine capsule 1hr before operation and 3rd dose 60mg capsule after 24hrs postoperative
Study NCT04294953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Each patient will receive a similar looking placebo capsule in the same time schedule. The placebo capsule will be prepared by hospital pharmacy to insure that active Duloxetine capsules will be indistinguishable from the placebo capsules contained starch
Study NCT03093376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effortful Control Camp
Description: An interactive, child-friendly camp. Effortful control (EC) camp is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 12 different exercises that teach inhibitory and attentional control, as well as visuospatial and working memory skills, will be administered.~Tasks will allow for scaffolding (Halperin et al, 2013), or incremental increases in difficulty of the games over time. EC camp will occur over 4 mornings from 9AM to 12PM, on two consecutive weekends.
Study NCT02957851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical Air
Study NCT02957851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMONO
Study NCT00504998 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 1 x 10e11 cfu 2 times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
Study NCT00504998 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 1 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
Study NCT00504998 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 2 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
Study NCT00504998 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dose Schedule: 3 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has less than Grade 1 or less toxicity.
Study NCT00504998 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 4 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
Study NCT04063475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyanoacrylate tissue adhesive beside sutures
Description: using cyanoacrylate tissue adhesive for FGG fixation
Study NCT04116580 — intervention group
Intervention type: OTHER
Intervention: RAAP - for Raw Apple in connection with re-contact with the raw apple according to an Ultra-Rush protocol
Study NCT04245774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine/Dextrose
Description: 7,5 mg (1.5 mL) of 0,5% hyperbaric bupivacaine (dextrose content 80 mg/mL) injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after intrathecal injection and than layed in supine position, finally they positioned in prone jack-knife.
Study NCT02510339 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Administration of two questionnairs during post operative visits.
Study NCT03991533 — intervention group
Intervention type: OTHER
Intervention: multiparametric MRI
Description: preoperative multiparametric MRI
Study NCT01220791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In vitro fertilization treatment for infertility
Description: IVF treatment
Study NCT01220791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: In vitro fertilization treatment for infertility
Description: IVF treatment
Study NCT03273855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: The intervention treatment is fecal microbiota transplantation made of frozen donor feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
Study NCT03273855 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: fecal microbiota transplantation
Description: The placebo group get fecal microbiota transplantation made of their own feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
Study NCT01824667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B-GOS
Study NCT01824667 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study NCT02426099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose spironolactone
Description: 4-week add-on low dose spironolactone in resistant hypertension
Study NCT02426099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine intensification of antihypertensive treatment
Description: 4-week guidelines oriented intensification of antihypertensive treatment
Study NCT04050033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evoke Device
Description: Subjects will undergo treatment with Evoke Device
Study NCT02396667 — intervention group
Intervention type: OTHER
Intervention: 5D ultrasound
Description: Measure the femur length by 5DLB to calculate fetal weight
Study NCT01858961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: Once a day
Study NCT01858961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Twice a day
Study NCT01858961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: Twice a day
Study NCT01858961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Three times a day
Study NCT01858961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon
Description: Once a week
Study NCT02144701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: Given PO
Study NCT02144701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis was not performed because of no differences in the clinical outcomes
Description: Correlative studies
Study NCT00581191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-351
Description: SLV-351 capsules taken once
Study NCT03207451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: Vorapaxar is the principle study drug and will be given to all subjects.
Study NCT03207451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar and Aspirin
Description: Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.
Study NCT03207451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar and Clopidogrel
Description: Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.
Study NCT03207451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar, Aspirin, and Clopidogrel
Description: Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.
Study NCT03170895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma; Advanced renal cell carcinoma
Study NCT01218802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10 mg. daily for 96 weeks
Description: Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
Study NCT01218802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will take a sugar pill daily for 96 weeks
Study NCT03170895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine Mepesuccinate Injection
Description: Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
Study NCT01244178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Intravenous Hyperinsulinemic therapy
Study NCT01244178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Standard Intravenous Insulin Therapy
Study NCT02656030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semispinalis cervicis resisted exercise
Description: semispinalis cervicis resisted exercise, 2 time per week, 6 weeks duration
Study NCT02656030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cranio-cervical flexion exercise
Description: cranio-cervical flexion exercise, 2 time per week, 6 weeks duration
Study NCT02656030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care, 2 time per week, 6 weeks duration
Study NCT00523432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Weekly doses via IV infusion. Dose will be assigned based on time of study entry.
Study NCT00523432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-779 (temsirolimus)
Description: Weekly 25mg dose via IV infusion.
Study NCT04151511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Erector Spinae Plane Block
Description: 1. Continuous Thoracic Epidural Thoracic Epidural Analgesia~2. Continuous Erector Spinae Plane Block
Study NCT04151511 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Continuous Erector Spinae Plane Block
Description: 1. Continuous Thoracic Epidural Thoracic Epidural Analgesia~2. Continuous Erector Spinae Plane Block
Study NCT02462265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi D & Oshadi R;
Description: Oshadi D (180mg/TID) \& Oshadi R (180mg TID) will be administrated;
Study NCT02462265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salvage therapy cytosar and mitoxantrone
Description: Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days)
Study NCT02123381 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preoperative radiotherapy
Description: Patients receive intensity modulated radiation therapy(IMRT) or image-guided radiation therapy(IGRT)from week 1 to week 4,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 40Gy/20f，GTV-N 40Gy/20f，CTV-T 40Gy/20f，CTV-N 40Gy/20f.
Study NCT02123381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400mg/m2/week, 2 hours,iv,at week 1;250mg/m2/week,1hour,iv,at week 2-4
Study NCT01894906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soluble Ferric Pyrophosphate
Study NCT01894906 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00976339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each.
Study NCT02944175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S
Study NCT02944175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously
Study NCT01231269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan without administration of contrast/without radiation
Study NCT02723240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-3373
Study NCT02933853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
Study NCT02933853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
Study NCT01356420 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholesterol supplementation
Description: Cholesterol supplementation may be achieved with SLOesterol instead of or in combination with egg yolk. SLOesterol is a powder formulation that contains cholesterol and natural emulsifier. It is considered a medical food developed by Solace Nutrition and available by prescription only.